EURneffy Receives EU Approval for Allergy Treatment
EURneffy marks a significant breakthrough in treating severe allergic reactions in both adults and children weighing 30 kg or more within the EU. This innovative delivery method for adrenaline is the first of its kind in over three decades, providing a vital option for individuals at risk of anaphylaxis.
Overview of the Approval Process
The approval from the European Commission follows a similar endorsement from the FDA in the United States. This decision was made after a thorough evaluation of one of the most extensive nasal spray development programs ever undertaken, which included studies with over 700 participants and more than 1,200 administrations.
Importance of Needle-Free Delivery
Dr. Antonella Muraro, MD PhD, a prominent expert in food allergies at the University of Padua, emphasizes the challenges associated with the underutilization of adrenaline due to the limitations of current therapies. Dr. Muraro stated, "Adrenaline is the only first-line treatment for allergic reactions, including anaphylaxis, yet significant barriers exist that prevent its effective use." The launch of EURneffy aims to address these challenges, offering a convenient and effective alternative for those who may struggle with traditional injectable adrenaline products.
Effects on Allergy Management
Richard Lowenthal, Co-Founder and CEO of ARS Pharma, highlighted the significance of this development: "Today’s approval is a landmark moment for the severe allergy community, marking the first novel method of adrenaline delivery in over three decades." The needle-free delivery system of EURneffy is expected to improve patient compliance, which may lead to a decrease in severe allergic reactions.
Assessment of Efficacy and Safety
Thorough assessments of the pharmacodynamics and pharmacokinetics of 2 mg EURneffy were conducted under various dosing conditions. The evaluations focused on self-administration by patients, dosing in pediatric populations, and effectiveness in situations that cause nasal congestion. This comprehensive analysis was crucial to ensure that EURneffy is reliable for patients in real-world scenarios.
Intellectual Property and Market Protection
EURneffy benefits from an eight-year data protection period for its development data, along with a ten-year marketing protection period that prevents generics from entering the EU market for a decade. Additionally, the composition and method patents for EURneffy in Europe are set to last until 2039, ensuring that ARS Pharmaceuticals maintains a competitive advantage.
Future Availability for Patients
ARS Pharma plans to make EURneffy available in select EU Member States later this year, partnering with a pharmaceutical company that has a strong market presence. This anticipated launch aims to provide patients with timely access to this life-saving medication.
Understanding Anaphylaxis and Allergy Responses
Type I allergic reactions, including anaphylaxis, are serious and potentially life-threatening conditions that demand immediate medical attention. In the EU, epinephrine remains the only approved treatment for such emergencies. While traditional adrenaline autoinjectors are effective, they have limitations, such as patients' reluctance to use them due to needle fear and the complexity of the devices, which can delay treatment during critical moments.
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative treatments for severe allergic reactions. The company is commercializing EURneffy in the EU as a groundbreaking intranasal epinephrine product designed for patients at risk of life-threatening anaphylaxis.
Frequently Asked Questions
What is EURneffy?
EURneffy is the first needle-free adrenaline nasal spray approved for treating anaphylaxis in the European Union.
How does EURneffy benefit patients?
By offering a needle-free alternative, EURneffy may improve adherence to emergency treatment protocols during allergic reactions.
What was the basis for EURneffy’s approval?
The approval was based on extensive clinical trials involving hundreds of participants, ensuring its efficacy and safety in treating severe allergic reactions.
When will EURneffy be available in the EU?
EURneffy is expected to be available to patients in select EU Member States by the end of 2024.
Who developed EURneffy?
EURneffy was developed by ARS Pharmaceuticals, a company committed to enhancing the safety of patients at risk of severe allergic reactions.
